Inside the Current Issue
 
Cover Story
2008 CS/SPD
Dept. of the Year

Self Study Series

Newswire
2008 Industry Guide
Purchasing Connection
Resources
Show Calendar
HPN ProductLink
Classifieds
Issue Archives
Advertise
About Us Home
Subscribe
Special Event Photos

Contact Us

KSR Publishing, Inc.
Copyright © 2008

People, Places, Processes & Products that Influence the Supply Chain

INSIDE THE CURRENT ISSUE

May 2007

Infection Connection

Infection Control Update

Statins linked to lower risk of infection in dialysis patients

Researchers at Johns Hopkins may have discovered an unintended benefit in the drugs millions of Americans take to lower their cholesterol: The medications, all statins, seem to lower the risk of a potentially lethal blood infection known as sepsis in patients on kidney dialysis. The study was published in the Journal of the American Medical Association (JAMA). Sepsis is the leading cause of death in non-coronary intensive care units in the United States, according to the Centers for Disease Control and Prevention. It also poses serious risk for kidney patients undergoing regular dialysis treatments. The Hopkins researchers cautioned that kidney dialysis patients should not necessarily ask their doctors to put them on statins until more studies are done to verify their findings.

Professor of Medicine, Director of the Welch Center and senior author Neil R. Powe, M.D., and his Johns Hopkins team followed 1,041 dialysis patients for 10 years. "Those taking statins had a 41 in a 1,000 chance of being hospitalized for sepsis, while the other group not taking statins had a 110 out of 1,000 risk. Although the overall absolute risk is relatively small, the statin group’s risk is dramatically lower," said Rajesh Gupta M.D., the study’s lead author, a senior medical resident at Hopkins when the study was conducted. The study’s authors also suppose that statins may work like penicillin, since the first statin was originally derived from a fungus which, it is theorized, secretes a statin as a way to starve other competing microorganisms that require cholesterol to survive.

Severe dengue cases often go unrecognized

Severe cases of a common travelers’ infection may not be recognized if doctors rely on the World Health Organization’s (WHO) guidelines for identifying it, according to a study published in the April 15 issue of The Journal of Infectious Diseases. Dengue is the most important emerging disease among international travelers, with a 30-fold increase in incidence over the past 50 years worldwide. Like malaria, dengue is transmitted to humans by mosquitoes. According to the WHO, dengue hemorrhagic fever (DHF) is characterized by fever, low platelet count, clinical evidence of leaking capillaries, and spontaneous bleeding or fragile blood vessels. The most serious cases can lead to shock and death. There is no cure but management of the disease’s effects can prevent the worst outcomes. Out of more than 200 patients treated for dengue infection at test sites over two years, less than 1% fit all four criteria necessary to meet the WHO definition of DHF. However, 11% had at least one manifestation of severe dengue disease, and a total of 23% required hospitalization due to dengue-related symptoms.

Connect with this month's featured Advertisers:

AHRMM
Alco Sales & Service Co.
APIC
Armstrong Medical Industries
Artromick International Inc.
Ascent Healthcare Solutions
ASHCSP
BD Medical
Bernard Hodes Group
Boehringer Labs
Cardinal Health
ChemDAQ Corp
ConvaTec
Enthermics Medical Systems
Exergen Corp
Gebauer Company
Global Healthcare Exchange
Healthmark Industries
IMS
InnerSpace Corp.
IRSG
Kimberly Clark Professional
Lionville Systems Inc.
Masimo
Millennium Marking Co.
Olympus America Inc.
Premier Healthcare
Ruhof Corporation
SciCan
SterilMed, Inc.
STERIS
Stretchair
TekTone Sound & Signal
TSK Products, Inc.
Uni-med
Arming against wounds to foster healing

by Susan Cantrell, ELS

Infected surgical wounds are risky business, both for the patient and for the hospital. They’re costly in terms of human suffering, where the price might even be death. Patients who suffer surgical-site infection (SSI) are twice as likely to die, 60% more likely to spend time in an ICU, and more than five times more likely to be readmitted to hospital.1 SSI causes longer, costlier hospital stays.1 They can be painful to the hospital’s pocketbook, to the tune of $1 to $10 billion in direct and indirect medical costs each year, according to the Centers for Disease Control and Prevention.2 Small wonder the hunt is on for better ways to care for surgical (and other types of) wounds.

Before the "cut"

Prior to surgery, the surgical staff scrub the patient’s skin to rid the site of pathogens. Unfortunately, there’s really no way to achieve skin sterilization.
So, what can you do about that dilemma? Kimberly-Clark has come up with a novel answer to the question: InteguSeal.

InteguSeal is a blue-violet-tinted, free-flowing, liquid cyanoacrylate contained in a glass ampule. It’s released by pressing on a plunger, just as if it were a large syringe, then painting the product on. As it’s painted on the skin surface, InteguSeal bonds to the skin and encases everything in its path, including bacteria. It does not need to be removed; eventually it just wears off. A real plus is that, because it’s a microbial sealant and not an antimicrobial, it doesn’t promote bacterial resistance. Who isn’t happy about that?

John Amat, vice president–global sales and marketing, Kimberly-Clark Health Care, Roswell, GA, described it in further detail: "The Kimberly-Clark InteguSeal Microbial Sealant seals and immobilizes pathogens to help protect against migration into surgical incisions, reducing the risk of skin flora contamination, a major source of SSI. InteguSeal is meant to be used following skin prep treatments and does not require the surgical team to change its preoperative process."

According to Amat, its virtues include its adaptability: "InteguSeal can be used with electrocautery, sutures, staples, and wound adhesives. It does not need to be removed for suture or closing. The film bonds to skin surfaces with different curvature, hair-content, or amounts or types of flora present. Wound contamination by the patient’s endogenous skin flora is a key factor in the development of SSI, and absolute skin sterilization prior to surgery is not possible. Having a solution like InteguSeal, which helps to prevent a patient’s own skin flora from contaminating the wound, will bring hospitals one step closer to reducing the risk of SSI. On prepped skin, pathogens from the patient’s own skin can be transferred into the surgical incision by any number of vehicles used over the course of the procedure, including irrigation fluids, gloves, instruments, sponges, or implants."

Amat told Healthcare Purchasing News that InteguSeal can very successfully take on the big-gun pathogens. "In an in vitro surgical-incision model, InteguSeal reduced the amount of methicillin-resistant Staphylococcus aureus recovered by 99.9%, Staphylococcus epidermidis by 99.5%, and Escherichia coli by 96.6%."

If you want to see InteguSeal in action, go to http://www.kchealthcare.com/integuseal/integvideo.html.

Closing up

Closing a wound after surgery also can contribute to the potential for infection, because bacteria can cling to needles and sutures as they are worked in and out of the skin. 3M has an answer to the problem for low-tension surgical wounds.

Caroline Krubsack, marketing analyst, 3M Company, St. Paul, MN, described the product, which can be used in lieu of needles and sutures or staples: "3M Steri-Strip S Surgical Skin Closure is a non-invasive, adhesive-based device designed to close low-tension surgical incisions or lacerations."

According to Krubsack, 3M Steri-Strip S Surgical Skin Closure’s virtues include the following:

• Fast application

• Good cosmetic results

• Precise wound-edge alignment and approximation

• Less potential for infection than sutures and staples

• Helps limit tissue trauma and patient discomfort

• Adjunct to suture closures for higher tension wounds or as reinforcement for wounds after early suture or staple removal

• Devices can be combined to achieve the length needed or to close a curved wound.

3M Steri-Strip S Surgical Skin Closure (formerly marketed as ClozeX) was found, in a study by Kuo et al "to be a safe and effective closure device. The cosmetic outcome seems to be at least as good as simple running suture. Physicians and patients were generally more satisfied with ClozeX. No difference was found in the rate of dehiscence or infection between the groups."3

To view a video demonstrating how to use 3M Steri-Strip S Surgical Skin Closure or to request a free trial, go to http://solutions.3m.com/wps/portal/3M/
en_US/SH/SkinHealth/brands/steri-strip/application/.

The silver lining in wound care

Unfortunately, not all wounds, surgical or otherwise, heal well or quickly. Ionic silver is a dynamite answer to many of those situations. Ionic silver has some important advantages going for it: it’s a natural broad-spectrum antibiotic; bacteria are actually attracted to it; and the silver is activated by wound exudate.

Mölnlycke Health Care US, LLC, Norcross, GA, is one company employing silver in their offering of wound dressings. Andrew Myers, director of marketing, described their new silver dressing: "Mepilex Ag is a new antimicrobial dressing that provides a unique combination of silver, Safetac technology, and fluid management. The dressing is indicated for the management of exudating wounds such as leg and foot ulcers, pressure ulcers, donor sites, and partial thickness burns. Mepilex Ag features patented Safetac soft silicone adhesive technology, which minimizes trauma to the wound bed and pain for the patient. The dressing also manages wound exudate effectively, which helps to reduce the risk of maceration. In vitro studies have demonstrated that Mepilex Ag kills common pathogens within 30 minutes and offers an effective sustained release of silver for up to 7 days."

Myers highlighted the need for healthcare givers to select the correct type of dressing for different kinds of wounds: "Clinicians are getting smarter about how and when they use specific dressings, recognizing it’s important to use the right dressing for the right wound type. Many patients have underlying factors, such as diabetes, that don’t permit them to heal as well as others. The right wound dressing can jump start the healing process."

Healing latex-free

Many dressings have latex as a component, and that’s perfectly fine for most of the population; however, for someone allergic to latex, the allergic reaction has the potential to be more dangerous to the patient than the wound. Reactions can run from an itchy, burning rash formed around an already painful wound to life-threatening anaphylactic shock. Some companies are addressing the problem with latex-free products.

Andover Healthcare, Inc, Salisbury, MA, recently released CoFlex LF2, a latex-free, foam, cohesive bandage they say sticks and performs as well as latex bandages. A gentle, non-irritating, open-cell foam absorbs and holds the latex-free cohesive, delivering a long-lasting and comfortable cohesive bond. An added attraction is that, because CoFlex LF2 is unaffected by water, wet dressings stick and hold in place. It can be used for treatment of edema, holding dressings in place, stabilizing infusion lines, and as a light compression wrap. It’s easy to tear, and it’s appropriate for extended wear because it doesn’t unravel.

You make a difference in healing

We are very fortunate to live in a time when there are so many options available for treating wounds. Unfortunately, there is no "one-size-fits-all" solution to wound care. Deciding which products to stock can be a big job. Budgets always have to be taken into consideration, too. There’s only one thing for purchasers and users to do: research, research, research. The time spent on research is well worth it; it can result in better quality of life—or perhaps life itself—for your facility’s patients. When you examine wound care products, never forget the wound is attached to a person who needs help. How you perform your job can make such a difference, a very important difference, to many, many people.

References

1. Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ. The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect Control Hosp Epidemiol 1999;20:725-730.

2. Perencevich EN, Sands KE, Cosgrove SE, Guadagnoli E, Meara E, Platt R. Health and economic impact of surgical site infections diagnosed after hospital discharge. Emerg Infect Dis [serial online] 2003 Feb. Available from URL: www.cdc.gov/ncidod/eid/vol9no2/02-0232.htm.

3. Kuo F, Lee D, Rogers GS. Prospective, randomized, blinded study of a new wound closure film versus cutaneous suture for surgical wound closure. Dermatol Surg 2006;32:676-681.